Research paperIn vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron
References (32)
- et al.
Hepatic monooxygenase activities in subjects with genetic defect in drug oxidation
Gastroenterology
(1983) - et al.
Protein measurement with the Folin phenol reagent
J Biol Chem
(1951) - et al.
The carbon monoxide binding pigment of liver microsomes
J Biol Chem
(1964) - et al.
Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast
Biochem Pharmacol
(1992) - et al.
The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects
Pharmacol Ther
(1990) - et al.
Antiemetic efficacy of high-dose metoclopramide: randomized trial with placebo and prochlorperazine in patients with chemotherapyinduced nausea and vomiting
New Engl J Med
(1981) - et al.
High-dose dexamethasone for cisplatinum-induced vomiting
Cancer Chemother Pharmacol
(1981) - et al.
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus dexamethasone
Cancer Treatm Rep
(1985) - et al.
Extrapyramidal reactions with high-dose metoclopramide
New Engl J Med
(1983) - et al.
Evidence that 5-hydroxytryptamine, receptors mediate cytotoxic drug and radiation-invoked emesis
Br J Cancer
(1987)
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients
Drugs
(1992)
Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy. Comparing tropisetron with optimised standard antiemetic therapy
Drugs
(1992)
Compassionate use of a 5 HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment
Drugs
(1992)
Tropisetron, a new 5 HT3-receptor antagonist, in the prevention of radiationinduced nausea, vomiting and diarrhoea
Drugs
(1992)
Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy
Cancer
(1993)
Tropisetron: A review of the clinical experience
Drugs
(1992)
Cited by (36)
Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists
2006, Journal of Clinical AnesthesiaCYP2D6 pharmacogenetics and phenoconversion in personalized medicine
2022, Expert Opinion on Drug Metabolism and ToxicologyPharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics
2019, Pharmacogenetics and GenomicsClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron
2017, Clinical Pharmacology and TherapeuticsRifampicin decreases exposure to sublingual buprenorphine in healthy subjects
2016, Pharmacology Research and Perspectives
Copyright © 1995 Published by Elsevier Inc.